Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on ≥ 1 line of endocrine therapy: systematic review and meta-analysis

Fig. 3

The Forrest plot for global PFS for patients with (A) previous use of fulvestrant; (B) visceral metastasis; (C) Forrest plot for global PFS comparing oral SERDS with fulvestrant. Note: PFS, progression-free survival; CI, confidence interval; HR, hazard ratio; HR+/HER2-, hormone receptor-positive and human epidermal growth factor receptor 2-negative; SERDs, selective oestrogen receptor degraders

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us